Table 1. Summary of baseline disease characteristics in patients from the biomarker evaluable or non-evaluable population.

	Non-evaluable population		Evaluable population
	mFOLFOX6	Aflibercept plus mFOLFOX6	mFOLFOX6	Aflibercept plus mFOLFOX6
	(N=57)	(N=49)	(N=60)	(N=70)
Gender: male/female	32/25	33/16	36/24	43/27
Age: median (min : max)	66 (44 : 87)	62 (29 : 75)	62 (37 : 81)	63 (41 : 79)
Age: <65/⩾65 years	27/30	28/21	38/22	42/25
Race: Caucasian/Asian/Black/other	41/16/0/0	37/11/0/1	49/11/0/0	60/9/1/0
Weight (kg): median (min : max)	68 (40 : 107)	70 (40 : 115)	73 (48 : 134)	71 (40 : 117)
BSA (m2): median (min : max)	1.8 (1 : 2)	1.8 (1 : 2)	1.8 (1 : 2)	1.8 (1 : 2)
Prior adjuvant chemotherapy: yes/no	50/7	45/4	55/5	63/7
Prior surgery: yes/no	35/22	27/22	26/34	29/41
Prior radiotherapy: yes/no	53/4	47/2	57/3	62/8
ECOG performance status: 0/1/2	55/2	46/3	60/0	69/1
Number of metastatic organs involved at baseline: 0/1/>1	0/16/41	0/15/34	1/15/44	0/12/58
Liver-only metastases: yes/no	15/42	20/29	18/42	14/56

Abbreviation: ECOG=Eastern Cooperative Oncology Group.